These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 23330348

  • 1. ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
    Oncology (Williston Park); 2012 Nov; 26(11):1072. PubMed ID: 23330348
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG, GRID study investigators.
    Lancet; 2013 Jan 26; 381(9863):295-302. PubMed ID: 23177515
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of regorafenib in colorectal cancer and GIST.
    Waddell T, Cunningham D.
    Lancet; 2013 Jan 26; 381(9863):273-5. PubMed ID: 23177516
    [No Abstract] [Full Text] [Related]

  • 4. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
    Italiano A, Cioffi A, Coco P, Maki RG, Schöffski P, Rutkowski P, Le Cesne A, Duffaud F, Adenis A, Isambert N, Bompas E, Blay JY, Casali P, Keohan ML, Toulmonde M, Antonescu CR, Debiec-Rychter M, Coindre JM, Bui B.
    Ann Surg Oncol; 2012 May 26; 19(5):1551-9. PubMed ID: 22065192
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L, Zhang Z, Yao H, Liu K, Wen Y, Xiong L.
    Drug Des Devel Ther; 2014 May 26; 8():2061-7. PubMed ID: 25378911
    [Abstract] [Full Text] [Related]

  • 6. Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
    Lyseng-Williamson KA.
    BioDrugs; 2013 Oct 26; 27(5):525-31. PubMed ID: 23975637
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Treatment of Regorafenib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib].
    Saito Y, Takahashi T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y.
    Gan To Kagaku Ryoho; 2018 Jan 26; 45(1):121-123. PubMed ID: 29362328
    [Abstract] [Full Text] [Related]

  • 9. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC, Wu CE, Chen JS, Tseng JH, Chiang KC, Liu YY, Tsai CY, Cheng CT, Chen TW, Jan YY, Yeh TS, Chen YY, Yeh CN.
    Anticancer Res; 2014 Sep 26; 34(9):5029-36. PubMed ID: 25202087
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Regorafenib in gastrointestinal stromal tumors.
    Sirohi B, Philip DS, Shrikhande SV.
    Future Oncol; 2014 Sep 26; 10(9):1581-7. PubMed ID: 25145429
    [Abstract] [Full Text] [Related]

  • 12. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
    Montemurro M, Gelderblom H, Bitz U, Schütte J, Blay JY, Joensuu H, Trent J, Bauer S, Rutkowski P, Duffaud F, Pink D.
    Eur J Cancer; 2013 Mar 26; 49(5):1027-31. PubMed ID: 23140824
    [Abstract] [Full Text] [Related]

  • 13. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
    Shinagare AB, Jagannathan JP, Kurra V, Urban T, Manola J, Choy E, Demetri GD, George S, Ramaiya NH.
    Eur J Cancer; 2014 Mar 26; 50(5):981-6. PubMed ID: 24388774
    [Abstract] [Full Text] [Related]

  • 14. Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany.
    Tamoschus D, Draexler K, Chang J, Ngai C, Madin-Warburton M, Pitcher A.
    Clin Drug Investig; 2017 Jun 26; 37(6):525-533. PubMed ID: 28361439
    [Abstract] [Full Text] [Related]

  • 15. Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
    Komatsu Y, Doi T, Sawaki A, Kanda T, Yamada Y, Kuss I, Demetri GD, Nishida T.
    Int J Clin Oncol; 2015 Oct 26; 20(5):905-12. PubMed ID: 25655899
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours.
    Kocakova I, Kocak I, Spelda S, Krejci E, Bencsikova B, Jureckova A, Vyzula R, Bortlicek Z, Strenkova J, Brabec P.
    Bratisl Lek Listy; 2015 Oct 26; 116(4):218-21. PubMed ID: 25773947
    [Abstract] [Full Text] [Related]

  • 19. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A, Boglione A.
    Recenti Prog Med; 2015 Jan 26; 106(1):17-22. PubMed ID: 25621775
    [Abstract] [Full Text] [Related]

  • 20. A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST.
    Blay JY.
    Cancer Treat Rev; 2011 Aug 26; 37(5):373-84. PubMed ID: 21195552
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.